润百颜产品系列
Search documents
华熙生物亮相进博会:从透明质酸到ECM核心关键活性物质,系统科学重构生命健康未来
Cai Jing Wang· 2025-11-07 03:13
Core Insights - The article highlights the advancements and innovations of Huaxi Biological in the field of extracellular matrix (ECM) science, showcasing its commitment to leading global research and development in anti-aging solutions [1][2][4]. Group 1: ECM Science and Research - Huaxi Biological has established a comprehensive system for ECM science, aligning its research with global life science advancements, and is recognized as a key player in the study of ECM components [2][3]. - The company is actively involved in the research of ECM as a significant aging marker, with international journals acknowledging ECM changes as a major indicator of aging by 2025 [2]. - Huaxi Biological's research integrates a "big omics cross-disciplinary" approach, focusing on the synergistic effects of key ECM substances, transitioning from a "single substance era" to a "system structure era" in anti-aging research [2][3]. Group 2: Innovation and Product Development - The company showcases its ECM research outcomes through innovative products, leveraging China's manufacturing capabilities and a leading pilot transformation platform with 64 pilot production lines [3][4]. - Huaxi Biological has developed a series of products aimed at rebuilding healthy ECM networks and enhancing cellular vitality, with notable achievements in the medical aesthetics sector [3][4]. - The company has received multiple domestic and international awards for its research in key materials like hyaluronic acid, demonstrating its ability to convert cutting-edge research into market-ready products [3][4]. Group 3: Global Expansion and Strategic Partnerships - Huaxi Biological is transitioning from "Chinese manufacturing" to "global standards," establishing a robust intellectual property protection network across over 30 countries and planning to set up a regional center in Europe [4][5]. - As of 2024, international sales of raw materials are projected to account for 49.19% of the company's raw material business revenue, with operations in over 70 countries [4]. - Recent strategic partnerships with companies like LG Household & Health Care and Xcell Therapeutics aim to enhance collaboration in synthetic biology and cell therapy, further solidifying Huaxi Biological's position in the global biopharmaceutical landscape [5][6].